Restoring apoptosis as a strategy for cancer gene therapy:: focus on p53 and mda-7

被引:72
作者
Lebedeva, IV
Su, ZZ
Sarkar, D
Fisher, PB
机构
[1] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA
关键词
gene therapy; programmed cell death; adenovirus; p53; ONYX-015; mda-7 (IL-24); clinical trials;
D O I
10.1016/S1044-579X(02)00134-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Understariding the molecular and genetic determinants of cancer will provide unique opportunities for developing rational and effective therapies. Malignant cells are frequently resistant to chemotherapy and radiation induced programmed cell death (apoptosis). This resistance can occur by mutations in the tumor suppressor gene p53. Strategies designed to replace this defective tumor suppressor protein, as well as forced expression of a novel cancer specific apoptosis inducing gene, melanoma differentiation associated gene-7 (mda-7), offer promise for restoring apoptosis in tumor cells. Conditional-replicating viruses that selectively induce cytolysis in tumor cells provides an additional means of targeting cancer cells for destruction. Although these approaches represent works in progress, future refinements will in all likelihood result in the next generation of cancer therapies. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:169 / 178
页数:10
相关论文
共 124 条
[61]  
Kemp CJ, 2001, CANCER RES, V61, P327
[62]   A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [J].
Khuri, FR ;
Nemunaitis, J ;
Ganly, I ;
Arseneau, J ;
Tannock, IF ;
Romel, L ;
Gore, M ;
Ironside, J ;
MacDougall, RH ;
Heise, C ;
Randlev, B ;
Gillenwater, AM ;
Bruso, P ;
Kaye, SB ;
Hong, WK ;
Kirn, DH .
NATURE MEDICINE, 2000, 6 (08) :879-885
[63]   p53: Puzzle and paradigm [J].
Ko, LJ ;
Prives, C .
GENES & DEVELOPMENT, 1996, 10 (09) :1054-1072
[64]  
Kock H, 1996, INT J CANCER, V67, P808
[65]   Identification of the functional interleukin-22 (IL-22) receptor complex -: The IL-10R2 chain (IL-10Rβ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes [J].
Kotenko, SV ;
Izotova, LS ;
Mirochnitchenko, OV ;
Esterova, E ;
Dickensheets, H ;
Donnelly, RP ;
Pestka, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (04) :2725-2732
[66]   Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation [J].
Kuball, J ;
Wen, SF ;
Leissner, J ;
Atkins, D ;
Meinhardt, P ;
Quijano, E ;
Engler, H ;
Hutchins, B ;
Maneval, DC ;
Grace, MJ ;
Fritz, MA ;
Störkel, S ;
Thüroff, JW ;
Huber, C ;
Schuler, M .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :957-965
[67]   The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells [J].
Lebedeva, IV ;
Su, ZZ ;
Chang, Y ;
Kitada, S ;
Reed, JC ;
Fisher, PB .
ONCOGENE, 2002, 21 (05) :708-718
[68]  
LEBEDEVA IV, 2002, UNPUB
[69]   p53, the cellular gatekeeper for growth and division [J].
Levine, AJ .
CELL, 1997, 88 (03) :323-331
[70]   P53 gene mutations:: Case study of a clinical marker for solid tumors [J].
Liu, MC ;
Gelmann, EP .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :246-257